Motixafortide

Haematopoietic stem and progenitor cells are anchored in the bone marrow by the CXCL12 (SDF-1) gradient acting through CXCR4. Motixafortide is a synthetic cyclic peptide, structurally derived from the polyphemusin family, that occupies the CXCR4 orthosteric pocket with sub-nanomolar affinity and dissociates unusually slowly — crystallographic work confirmed a deep, long-lived binding mode. That prolonged occupancy is the practical difference from plerixafor: a single dose sustains mobilisation across an entire apheresis window rather than requiring daily redosing. As a class, CXCR4 blockade also mobilises malignant cells out of their protective niche, which is the rationale for the ongoing combination trials in leukaemia and pancreatic cancer. Histamine release from mast cells, which also express CXCR4, drives the injection-site and systemic reactions that require premedication.

Targets: CXCR4 chemokine receptor, CXCL12 / SDF-1 signalling axis

• · 1.25 mg/kg subcutaneously — for an 80 kg patient that is 100 mg, split across two injections. Premedicate with an antihistamine, a leukotriene inhibitor such as montelukast and an analgesic, because histamine-mediated reactions are near-universal without it. A second dose may be given if the first apheresis does not reach the target CD34 yield.

Work out your exact syringe units →

• very commonInjection-site reactions— Pain, erythema and pruritus in the great majority of patients — histamine-driven and the reason for mandatory premedication.
• very commonPruritus and flushing
• very commonLeukocytosis— Expected pharmacology — mobilisation is the point.
• commonTransient hypertension or hypotension— Blood pressure is monitored around dosing.
• commonNausea and vomiting
• commonBack pain and paraesthesia
• uncommonSystemic hypersensitivity or anaphylaxis— Patients are observed after dosing with resuscitation equipment available.

• Known serious hypersensitivity to motixafortide.
• Pregnancy — embryo-fetal toxicity in animals.
• Leukaemia with circulating blasts, where mobilising malignant cells is a theoretical hazard rather than a benefit.

• synergyFilgrastim / G-CSF — The approved use is strictly combination — four days of G-CSF priming then motixafortide. Neither works as well alone.
• redundantplerixafor — Same receptor, same purpose. Motixafortide's advantage is more single-apheresis collections; plerixafor's is decades of experience and lower cost.
• synergyAntihistamines and montelukast — Not optional — premedication is written into the administration protocol to blunt histamine release.

• · Peripheral blood CD34 count on the morning of apheresis to confirm mobilisation.
• · Full blood count including white cell count, which rises sharply by design.
• · Blood pressure and observation for hypersensitivity for at least an hour after dosing.
• · Apheresis CD34 yield per collection — the actual endpoint that matters.

FDA approved in 2023 for stem cell mobilisation in multiple myeloma. Hospital transplant-centre use only.

• Crees et al. 2023, GENESIS phase 3 trial of motixafortide plus G-CSF for stem cell mobilisation, Nature Medicine (trial)
• Structural basis of motixafortide binding in the CXCR4 chemokine receptor, 2022 (preclinical)
• FDA prescribing information for Aphexda (label)

Haematopoietic stem and progenitor cells sit in the marrow because CXCL12, also called SDF-1, is produced by marrow stromal and endothelial cells and holds them there through CXCR4. Break the tether and they wash into the blood, which is exactly what an apheresis machine wants. What separates motixafortide from plerixafor is not which receptor it blocks but how long it stays there. It binds the CXCR4 orthosteric pocket with sub-nanomolar affinity and, more importantly, dissociates very slowly — structural work on the binding mode shows a deep insertion into the transmembrane pocket with the naphthylalanine at position 3 reaching into a subpocket that the small-molecule bicyclams cannot access. Slow off-rate means one evening dose covers the following day's entire apheresis window, whereas plerixafor's faster dissociation forces daily redosing for multi-day collections. The mobilisation kinetics reflect that directly: peripheral CD34 counts peak roughly 10 to 14 hours after injection and stay usefully elevated, which is why the drug is given the night before collection. Two secondary consequences matter. First, CXCR4 blockade does not only mobilise healthy stem cells; it mobilises malignant cells out of the protective marrow niche too, which is the rationale behind the wider oncology programme in acute myeloid leukaemia and pancreatic cancer, and the reason mobilising a patient with circulating blasts is a theoretical hazard rather than a benefit. Second, mast cells express CXCR4 and Mas-related G protein-coupled receptor X2 is activated by many cationic peptides; motixafortide is highly cationic and triggers substantial histamine release. That is why injection-site pain, erythema, pruritus and flushing are near-universal without premedication, and why an antihistamine plus a leukotriene receptor antagonist plus an analgesic is written into the administration protocol rather than left to preference.

The injection hurts, and that is not a trivial observation — injection-site pain, erythema and pruritus affect the great majority of patients and are the most common reason the experience is described as unpleasant. Skipping or under-dosing the premedication turns a manageable reaction into a memorable one. Systemic hypersensitivity including anaphylaxis is uncommon but is why the observation period exists. Beyond the drug itself, the failure modes are logistical: the injection has to land in a 10 to 14 hour window before an apheresis slot that was booked days earlier, and a schedule slip wastes an expensive dose and a chair. The clinical contraindication that matters is leukaemia with circulating blasts, because mobilising malignant cells is the opposite of what you want before a transplant. And the honest framing of the drug's value is worth stating: this is not an antitumour agent. It gets a graft collected in one session instead of three or four. That is a real benefit — fewer central line days, fewer apheresis complications, faster to transplant — but it is a logistics benefit, not a survival one, and the wider CXCR4 oncology programme that gave rise to the molecule has not yet delivered an approved antitumour indication.

1. —Days 1 to 4 before dosing — Filgrastim priming at 10 micrograms per kg daily for four days. This is not optional — the approved use is strictly combination, and neither agent works as well alone.
2. 1.25 mgEvening of day 4, 10 to 14 hours before apheresis — 1.25 mg per kg subcutaneously, which is 1250 micrograms per kg. For an 80 kg patient that is 100 mg total, split across two injections. Premedicate with an antihistamine, a leukotriene receptor antagonist such as montelukast, and an analgesic — the histamine release is near-universal without it.
3. 1.25 mgEvening of day 5, if needed — A second identical dose may be given if the first apheresis did not reach the target CD34 yield. Two doses is the ceiling — this is a mobilisation event, not a course of therapy.

• CXCR4 chemokine receptor — Sub-nanomolar, with an unusually slow dissociation rate — the residence time, not the affinity number, is the clinically distinguishing property

  Competitive orthosteric blockade of CXCL12 binding, releasing haematopoietic stem and progenitor cells from the marrow niche into the circulation for 10 to 14 hours and beyond.

• CXCL12 / SDF-1 signalling axis — Blocked indirectly by receptor occupancy

  Loss of the retention gradient. Also disrupts the niche protection that shields malignant cells from chemotherapy, which is the basis of the wider oncology programme.

• Mast cell degranulation, via cationic peptide-driven histamine release

  The near-universal injection-site and systemic reactions. Not an immune allergy in most cases but direct degranulation, which is why an antihistamine and montelukast blunt it so effectively.

• GENESIS Phase 3 · n=122 · 2023

  Proportion of patients collecting at least 6 million CD34+ cells per kg within two apheresis sessions. Motixafortide plus G-CSF achieved this in the large majority versus a small minority with G-CSF plus placebo, and a high proportion reached target in a single session.

Injection-site reactions and flushing begin within minutes of the dose. White cell count rises within a few hours. Peripheral CD34 counts peak at roughly 10 to 14 hours, which is why the drug goes in the evening before a morning collection, and the mobilisation window stays open long enough to cover a full apheresis session. Plasma levels are largely gone by then — effective plasma half-life is about 2 hours — which is the clearest demonstration that receptor residence time rather than drug concentration is what governs this drug. The whole clinical event is over in 48 hours.

This drug only exists inside a combination. Four days of filgrastim priming come first, then motixafortide the evening before apheresis. Neither agent alone reaches the collection targets the combination does. The premedication stack — an H1 antihistamine, montelukast and an analgesic, often with an H2 blocker added — is written into the administration protocol because the histamine release is essentially universal without it, and centres that skipped it in early experience found out why it is there. Patients are observed with resuscitation equipment available. Beyond that there is almost nothing to interact with: no CYP metabolism, no transporter issues, catabolism to amino acids. The relationship with plerixafor is substitution rather than combination — same receptor, same purpose, and there is no reason to give both. Where the interesting future stacking lies is outside mobilisation entirely: CXCR4 blockade to evict leukaemic blasts from the protective niche before chemotherapy, and to remodel the immunosuppressive stroma of pancreatic cancer before checkpoint blockade. Those are trials, not practice.

Against plerixafor, the receptor and the purpose are identical and the difference is residence time. Motixafortide's slow off-rate gives a 10 to 14 hour peak and a single dose that covers a full apheresis window, where plerixafor peaks at 6 to 9 hours and typically needs daily redosing for multi-day collections. GENESIS showed a large advantage in single-session collection. Plerixafor's advantages are fifteen years of experience, generic pricing and a markedly gentler injection-site profile — plerixafor's local reactions are mild where motixafortide's are the defining complaint. If the question is which drug gets a difficult mobiliser collected in one visit, motixafortide. If the question is which drug is the sensible default for an average patient in a cost-constrained system, plerixafor still. Against G-CSF alone, either agent transforms the outcome in poor mobilisers. Against the older approach of chemomobilisation with cyclophosphamide plus G-CSF, both CXCR4 antagonists avoid the neutropenic fever and hospitalisation that chemomobilisation carries.

Not characterised, and monthly is the wrong unit — this is a one-off or at most two-off event in a transplant workup, billed as a single treatment course. It is substantially more expensive than generic plerixafor per event, and the health-economic argument for it rests on fewer apheresis sessions and fewer central line days rather than on drug price.

• ?Absolute subcutaneous bioavailability is not reported in the label and is left null.
• ?The sub-nanomolar CXCR4 affinity is the widely reported figure for this peptide family but I did not resolve a primary binding study in this session; the structural paper cited describes the binding mode rather than a measured Kd.
• ?The GENESIS enrolment of 122 is as commonly cited; I resolved the publication record but not participant-level detail from the full text.
• ?The mast cell mechanism for the injection reactions — direct cationic peptide-driven degranulation, possibly through MRGPRX2 — is a plausible and widely repeated explanation but I did not resolve a primary source demonstrating it for this specific molecule.
• ?Whether CXCR4 blockade delivers antitumour benefit outside mobilisation is unresolved. The leukaemia and pancreatic cancer programmes are ongoing and have not produced an approval.
• ?The Core record lists the half-life as not something to quote precisely; the label's roughly 2-hour effective plasma half-life is now included here, but it genuinely does not predict duration of effect.

• Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial Crees ZD, Rettig MP, Jayasinghe RG, et al., Nature Medicine, 2023 · PMID 37069359

  GENESIS. The registration trial and the source of the single-apheresis collection claim that is the drug's entire selling point.

• Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor Rebolledo-Bustillo M, Garcia-Gomez D, Davila EM, et al., International Journal of Molecular Sciences, 2023 · PMID 36901829

  The computational and structural account of why this peptide sits so deeply and for so long in the CXCR4 pocket, which is the mechanistic basis for the once-daily dosing advantage over plerixafor.

• APHEXDA (motixafortide) for injection — US prescribing information BioLineRx, FDA prescribing information

  Source of the full amino acid sequence, the 27 L central volume, over 99 percent protein binding, 46.5 L/h apparent clearance, roughly 2-hour effective plasma half-life and the 80 to 82 percent urinary excretion of catabolites with no parent drug detected.